Nath Bio-Genes (India) Ltd Q4 FY26 Results

Summary

Nath Bio-Genes (I) Ltd concluded FY26 with a robust 19.13% year-on-year growth in revenue from operations, reaching ₹431.60 crore. While the full-year profit from operations (before other income, finance cost, and exceptional items) saw a marginal increase to ₹48.59 crore, the company witnessed a significant 202.24% surge in this profit metric for Q4 FY26, totaling ₹5.59 crore despite a decline in quarterly revenue. The Board also recommended a dividend of ₹2 per equity share for FY25-26 and approved a substantial increase in the Managing Director's remuneration, subject to shareholder approval.

Key Highlights

1. 1

   Nath Bio-Genes reported full-year FY26 revenue from operations of ₹431.60 crore (43,159.72 Lacs), marking a 19.13% increase compared to ₹362.31 crore (36,230.81 Lacs) in FY25.

2. 2

   However, revenue from operations for Q4 FY26 stood at ₹45.69 crore (4,569.36 Lacs), a 7.48% decline year-on-year from ₹49.39 crore (4,938.76 Lacs) in Q4 FY25.

3. 3

   Profit from operations (before other income, finance cost, and exceptional items) for Q4 FY26 significantly increased by 202.24% to ₹5.59 crore (558.97 Lacs), up from ₹1.85 crore (184.94 Lacs) in the same quarter last year.

4. 4

   For the full financial year FY26, profit from operations (before other income, finance cost, and exceptional items) saw a marginal growth of 0.17% to ₹48.59 crore (4,858.84 Lacs), compared to ₹48.50 crore (4,850.36 Lacs) in FY25.

5. 5

   The Board recommended a dividend of ₹2 per equity share, representing 20% of the nominal value, for the financial year 2025-26, subject to shareholder approval.

6. 6

   The remuneration of Mr. Satish Kagliwal, Managing Director, was approved to increase from ₹66,00,000 per annum to ₹1,44,00,000 per annum, effective January 1, 2026, pending shareholder approval.